Skip to main content
Clinical Trials/EUCTR2010-024214-54-BE
EUCTR2010-024214-54-BE
Active, not recruiting
Phase 1

Exploratory study to assess facial tolerability after daily application of several concentrations and formulations containing CD5789 in acne subjects

GALDERMA R&D SNC0 sites60 target enrollmentStarted: February 14, 2011Last updated:
DrugsZorac®

Overview

Phase
Phase 1
Status
Active, not recruiting
Sponsor
GALDERMA R&D SNC
Enrollment
60

Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • Male or female subject aged from 18 to 35 years old
  • The subject has medical diagnosis of moderate to severe acne vulgaris on the face
  • The subject has, on the face, at least 20 inflammatory lesions and 30 non\-inflammatory lesions
  • If female of childbearing potential,she agrees to use a highly effective double\-barrier contraception method for the duration of the study and one month after the last product application.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years) no
  • F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • The subject has severe forms of acne requiring systemic treatment (acne conglobata, acne fulminans) or secondary acne form (chloracne, drug\-induced acne, etc.)
  • The subject has a known allergy or sensitivity to any of the components of the study products

Investigators

Sponsor
GALDERMA R&D SNC

Similar Trials